Turning Point Brands Q2 2026 earnings: Modern Oral growth lifts sales as spending weighs on profit

Turning Point Brands’ Q2 2026 net sales rose 22.6% to $142.9 million, led by a 128% increase in Modern Oral net sales to $68.4 million. Diluted EPS fell to $0.18 from $0.79, while adjusted EBITDA declined 50.0% to $15.2 million as SG&A nearly doubled amid sales, marketing and freight spending. Reported gross profit benefited from a tariff refund, and the company raised full-year Modern Oral gross and net sales guidance while providing adjusted EBITDA guidance of $70 million to $90 million.